ABSTRACT
Background Low muscle oxidative capacity is an extrapulmonary manifestation of chronic obstructive pulmonary disease (COPD) with unclear etiology. We sought to determine clinical and behavioral features associated with muscle oxidative capacity in smokers with and without COPD and never smoker individuals.
Methods 243 adults enrolled in the Muscle Health Study, an observational study ancillary to COPDGene. Gastrocnemius oxidative capacity was measured by near-infrared spectroscopy from muscle oxygen uptake recovery rate constant (k). Physical activity by accelerometry (vector magnitude units, VMU/min). Pulmonary assessments included spirometry (FEV1%predicted), diffusing capacity (DLCO), and quantitative chest computed tomography (CT). Eighty-seven variables related to COPD features were considered. Variables selected by univariate analysis of log-transformed k with p≤0.20, and filtered by machine learning, were entered into multivariable linear regression to determine association with k.
Results 241(99%) participants were allocated to analysis. FEV1%predicted, DLCO, CT, pack-years, age and VMU/min were among 24 variables selected by univariate analysis. After machine learning filtering on 161(66%) cases with complete data, 11 variables were included in multivariable analysis. Only FEV1%predicted, age and race were significantly associated with k (R2=0.26). Model coefficients equate a 10% lower FEV1%predicted to a 4.4% lower k, or 10-years of aging to a 9.7% lower k. In 118 cases with CT available, FEV1%predicted and age remained associated with k (R2=0.24). Physical activity was not retained in any model.
Conclusions Locomotor muscle oxidative capacity was positively associated with FEV1%predicted and negatively associated with age. Physical activity or radiographic COPD manifestations were not significantly associated with muscle oxidative impairment.
Competing Interest Statement
Alessandra Adami is supported by National Health Institute grant R01HL151452. Fenghai Duan reports consulting fee from EarlyDiagnostics Inc. Richard Casaburi reports consulting fees from Inogen, Harry Rossiter is supported by grants from National Health Institute (R01HL151452, R01HL166850, R01HL153460, P50HD098593, R01DK122767) and the Tobacco Related Disease Research Program (T31IP1666). He reports consulting fees from the National Health Institute RECOVER-ENERGIZE working group (1OT2HL156812), and is involved in contracted clinical research with United Therapeutics, Genentech, Regeneron, Respira, Mezzion and Intervene Immune. He is a visiting Professor at the University of Leeds, UK. All other authors have nothing to disclose.
Funding Statement
This work was supported by National Heart, Lung, and Blood Institute grant R01HL151452; the Swiss National Science Foundation (SNSF) grants P300P3_151705. P300PB_167767; and by the Pulmonary Education and Research Foundation. This work was also supported by National Heart, Lung, and Blood grants U01 HL089897 and U01 HL089856 and by NIH contract 75N92023D00011. The COPDGene study (NCT00608764) has also been supported by the COPD Foundation through contributions made to an Industry Advisory Committee that has included AstraZeneca, Bayer Pharmaceuticals, Boehringer-Ingelheim, Genentech, GlaxoSmithKline, Novartis, Pfizer, and Sunovion.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was approved by the Institutional Review Board of The Lundquist Institute at Harbor-UCLA Medical Center (20403-01) and conducted in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.
Subject Area
Reviews and Context
0
Comment
0
TRIP Peer Reviews
0
Community Reviews
0
Automated Services
0
Blogs/Media
Author Videos